NNZ-2591 + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Phelan-McDermid Syndrome
Conditions
Phelan-McDermid Syndrome
Trial Timeline
Nov 12, 2025 → Nov 15, 2027
NCT ID
NCT07281079About NNZ-2591 + Placebo
NNZ-2591 + Placebo is a phase 3 stage product being developed by Neuren Pharmaceuticals for Phelan-McDermid Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07281079. Target conditions include Phelan-McDermid Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07281079 | Phase 3 | Recruiting |
| NCT04379869 | Phase 1 | Completed |
Competing Products
1 competing product in Phelan-McDermid Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NNZ-2591 | Neuren Pharmaceuticals | Phase 2 | 47 |